Tesaro Inc (TSRO)
Trading: HOLD @ $74.06
Signal Strength: STRONG
Tesaro Inc (NASDAQ:TSRO) currently has positive MACD of 4.8011. Currently the signal line is greater than the MACD line signalling a bullish movement.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Moving Average Convergence/Divergence (MACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).
Calculation:: Moving Average Convergence Divergence (MACD);
1) MACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of MACD Line;
3) MACD Histogram: MACD Line - Signal Line;
PROFILE: Tesaro Inc (TSRO)
Stock Exchange: NASDAQ
Company: Tesaro Inc
Ticker Codes: | TSRO | NASDAQ:TSRO |
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
|CMTL Comtech Telecom||29.33||15.5||254,586||0.47||BULLISH|
|AGEN Agenus Inc||2.66||13.2||905,828||0.03||BULLISH|
|MNTA Momenta Pharma||13.2||9.3||3,323,792||0.26||BULLISH|
|ELGX Endologix Inc||0.73||9||655,296||0||BULLISH|
|CRBP Corbus Pharma||6.99||5||495,220||0.1||BULLISH|
|TGLS Tecnoglass Inc||9.29||3||7,143||0.06||BULLISH|
|ATRA Atara Biotherap||40.83||2.9||207,020||0.36||BULLISH|
|GOGL Golden Ocean||7.04||2.8||85,615||0.07||BULLISH|
|OTIC Otonomy Inc||2.36||2.6||480,000||0.01||BULLISH|